- Home
- CDIO vs PULM Comparison
CDIO vs PULM Comparison
Compare CDIO & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDIO | PULM |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CDIO | PULM |
|---|---|---|
| Price | $2.03 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.4K | 31.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | $171,906.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.97 | $1.16 |
| 52 Week High | $7.91 | $7.20 |
Technical Indicators
Market Signals| Indicator | CDIO | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 66.45 |
| Support Level | $1.68 | $1.21 |
| Resistance Level | $2.13 | $2.28 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.02 | 90.00 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).